Primary biliary cirrhosis. Is (and how much of) the pathology preventible?

Yaron Bar-Dayan, M. Eric Gershwin, Yaîr Levi, Howard Amital, Yehuda Shoenfeld

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease, which is invariably fatal. Circumstantial and indirect evidence suggests that autoimmune mechanisms have a role in the genesis of PBC. Antimitochondrial antibodies (AMA) are highly sensitive and specific markers that can predict the development of the disease in a healthy individual. Long-term administration of ursodeoxycholic acid (UDCA), a naturally occurring bile acid, safely slows the progression of PBC, delays the need for liver transplantation, and postpones death. An effort should be made to identify the patients with PBC in the asymptomatic stage by the presence of AMA and to conduct a clinical trial in order to assess the benefit of long-term administration of UDCA on the prevention of the overt disease in these individuals.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
JournalImmunologic Research
Volume18
Issue number2
StatePublished - 1998

Fingerprint

Biliary Liver Cirrhosis
Pathology
Ursodeoxycholic Acid
Antibodies
Bile Acids and Salts
Liver Transplantation
Liver Diseases
Clinical Trials

Keywords

  • Antimitochondrial antibodies
  • Prediction prevention
  • Primary biliary cirrhosis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Immunology

Cite this

Bar-Dayan, Y., Gershwin, M. E., Levi, Y., Amital, H., & Shoenfeld, Y. (1998). Primary biliary cirrhosis. Is (and how much of) the pathology preventible? Immunologic Research, 18(2), 117-123.

Primary biliary cirrhosis. Is (and how much of) the pathology preventible? / Bar-Dayan, Yaron; Gershwin, M. Eric; Levi, Yaîr; Amital, Howard; Shoenfeld, Yehuda.

In: Immunologic Research, Vol. 18, No. 2, 1998, p. 117-123.

Research output: Contribution to journalArticle

Bar-Dayan, Y, Gershwin, ME, Levi, Y, Amital, H & Shoenfeld, Y 1998, 'Primary biliary cirrhosis. Is (and how much of) the pathology preventible?', Immunologic Research, vol. 18, no. 2, pp. 117-123.
Bar-Dayan, Yaron ; Gershwin, M. Eric ; Levi, Yaîr ; Amital, Howard ; Shoenfeld, Yehuda. / Primary biliary cirrhosis. Is (and how much of) the pathology preventible?. In: Immunologic Research. 1998 ; Vol. 18, No. 2. pp. 117-123.
@article{7011970ad501409cb4fd4021f7f7150b,
title = "Primary biliary cirrhosis. Is (and how much of) the pathology preventible?",
abstract = "Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease, which is invariably fatal. Circumstantial and indirect evidence suggests that autoimmune mechanisms have a role in the genesis of PBC. Antimitochondrial antibodies (AMA) are highly sensitive and specific markers that can predict the development of the disease in a healthy individual. Long-term administration of ursodeoxycholic acid (UDCA), a naturally occurring bile acid, safely slows the progression of PBC, delays the need for liver transplantation, and postpones death. An effort should be made to identify the patients with PBC in the asymptomatic stage by the presence of AMA and to conduct a clinical trial in order to assess the benefit of long-term administration of UDCA on the prevention of the overt disease in these individuals.",
keywords = "Antimitochondrial antibodies, Prediction prevention, Primary biliary cirrhosis, Ursodeoxycholic acid",
author = "Yaron Bar-Dayan and Gershwin, {M. Eric} and Ya{\^i}r Levi and Howard Amital and Yehuda Shoenfeld",
year = "1998",
language = "English (US)",
volume = "18",
pages = "117--123",
journal = "Immunologic Research",
issn = "0257-277X",
publisher = "Humana Press",
number = "2",

}

TY - JOUR

T1 - Primary biliary cirrhosis. Is (and how much of) the pathology preventible?

AU - Bar-Dayan, Yaron

AU - Gershwin, M. Eric

AU - Levi, Yaîr

AU - Amital, Howard

AU - Shoenfeld, Yehuda

PY - 1998

Y1 - 1998

N2 - Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease, which is invariably fatal. Circumstantial and indirect evidence suggests that autoimmune mechanisms have a role in the genesis of PBC. Antimitochondrial antibodies (AMA) are highly sensitive and specific markers that can predict the development of the disease in a healthy individual. Long-term administration of ursodeoxycholic acid (UDCA), a naturally occurring bile acid, safely slows the progression of PBC, delays the need for liver transplantation, and postpones death. An effort should be made to identify the patients with PBC in the asymptomatic stage by the presence of AMA and to conduct a clinical trial in order to assess the benefit of long-term administration of UDCA on the prevention of the overt disease in these individuals.

AB - Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease, which is invariably fatal. Circumstantial and indirect evidence suggests that autoimmune mechanisms have a role in the genesis of PBC. Antimitochondrial antibodies (AMA) are highly sensitive and specific markers that can predict the development of the disease in a healthy individual. Long-term administration of ursodeoxycholic acid (UDCA), a naturally occurring bile acid, safely slows the progression of PBC, delays the need for liver transplantation, and postpones death. An effort should be made to identify the patients with PBC in the asymptomatic stage by the presence of AMA and to conduct a clinical trial in order to assess the benefit of long-term administration of UDCA on the prevention of the overt disease in these individuals.

KW - Antimitochondrial antibodies

KW - Prediction prevention

KW - Primary biliary cirrhosis

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=0031790320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031790320&partnerID=8YFLogxK

M3 - Article

C2 - 9844830

AN - SCOPUS:0031790320

VL - 18

SP - 117

EP - 123

JO - Immunologic Research

JF - Immunologic Research

SN - 0257-277X

IS - 2

ER -